BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/14/2020 1:53:48 PM | Browse: 571 | Download: 1040
 |
Received |
|
2020-03-18 02:26 |
|
Peer-Review Started |
|
2020-03-18 02:29 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-05-28 21:17 |
|
Revised |
|
2020-07-06 05:04 |
|
Second Decision |
|
2020-09-08 10:57 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-09-08 20:36 |
|
Articles in Press |
|
2020-09-08 20:36 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-09-23 22:59 |
|
Typeset the Manuscript |
|
2020-10-13 00:34 |
|
Publish the Manuscript Online |
|
2020-10-14 13:53 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Achievement of complete response to nivolumab in a patient with advanced sarcomatoid hepatocellular carcinoma: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shu-Guang Zhu, Hai-Bo Li, Ze-Nan Yuan, Wei Liu, Qing Yang, Ying Cheng, Wen-Jing Wang, Guo-Ying Wang and Hua Li |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National 13th Five-Year Science and Technology Plan Major Projects of China |
2017ZX10203205-006-001 |
| Sci-tech Research Development Program of Guangzhou City |
201607010024 |
| Science and Technology Planning Project of Guangdong Province |
2017B020209004 |
|
| Corresponding Author |
Guo-Ying Wang, MD, PhD, Doctor, Surgeon, Department of Hepatic Surgery and Liver Transplantation, The Third Affiliated Hospital of Sun Yat-Sen University, No. 600 Tianhe Road, Tianhe District, Guangzhou 510000, Guangdong Province, China. wanggy3@126.com |
| Key Words |
Sarcomatoid hepatocellular carcinoma; Hepatocellular carcinoma; Programmed death-ligand 1; Immunotherapy; Nivolumab; Case report |
| Core Tip |
Here, we report a rare case of advanced sarcomatoid hepatocellular carcinoma (SHC), which was successfully treated with the anti-programmed cell death 1 antibody. To the best of our knowledge, this is the first case report on the successful treatment of advanced SHC using immunotherapy. |
| Publish Date |
2020-10-14 13:53 |
| Citation |
Zhu SG, Li HB, Yuan ZN, Liu W, Yang Q, Cheng Y, Wang WJ, Wang GY, Li H. Achievement of complete response to nivolumab in a patient with advanced sarcomatoid hepatocellular carcinoma: A case report. World J Gastrointest Oncol 2020; 12(10): 1209-1215 |
| URL |
https://www.wjgnet.com/1948-5204/full/v12/i10/1209.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v12.i10.1209 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
